Voglio sapere a riguardo di…

48280

Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices
Picturing Antiquity. Notice is hereby given of the following determinations: I
hereby determine that certain additional objects being imported from abroad pursuant to agreements with their foreign owners or custodians for temporary display in the aforesaid exhibition at The J. Paul Getty Museum at the Getty Villa, Pacific Palisades, California, and at possible additional exhibitions or venues yet to be determined, are of cultural significance, and, further, that their temporary exhibition or display within the United States as aforementioned is in the national interest. I have ordered that Public Notice of these determinations be published in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Chi D. Tran, Program Administrator, Office of the Legal Adviser, U.S. Department of State telephone: 2026326471; email:
section2459@state.gov. The mailing address is U.S. Department of State, L/PD, 2200 C Street NW, SA5, Suite 5H03, Washington, DC 205220505.
SUPPLEMENTARY INFORMATION: The foregoing determinations were made pursuant to the authority vested in me by the Act of October 19, 1965 79 Stat.
985; 22 U.S.C. 2459, Executive Order 12047 of March 27, 1978, the Foreign Affairs Reform and Restructuring Act of 1998 112 Stat. 2681, et seq.; 22 U.S.C.
6501 note, et seq., Delegation of Authority No. 234 of October 1, 1999, and Delegation of Authority No. 2363
of August 28, 2000.
Matthew R. Lussenhop, Acting Assistant Secretary, Bureau of Educational and Cultural Affairs, Department of State.
FR Doc. 202118447 Filed 82621; 8:45 am BILLING CODE 471005P

OFFICE OF THE UNITED STATES
TRADE REPRESENTATIVE
Request for Comments on Certain Products Exclusions Related to COVID19: Chinas Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation Office of the United States Trade Representative USTR.
ACTION: Notice and request for comments.
lotter on DSK11XQN23PROD with NOTICES1

AGENCY:

In prior notices, the U.S.
Trade Representative modified the action in the Section 301 investigation of Chinas acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain
SUMMARY:

VerDate Sep<11>2014

17:52 Aug 26, 2021

Jkt 253001

medical-care products needed to address the COVID19 pandemic. These exclusions are scheduled to expire on September 30, 2021. In light of developments in the production capacity of the United States in the subject products and continuing efforts in the battle against COVID19, USTR is requesting public comments on whether to extend particular exclusions past September 30, 2021.
DATES:
August 27, 2021: The public docket on the web portal at https
comments.USTR.gov will open for parties to submit comments.
September 27, 2021 at 11:59 p.m. ET:
To be assured of consideration, submit written comments on the public docket by this time.
ADDRESSES: You must submit all comments through the online portal:
https comments.USTR.gov.
FOR FURTHER INFORMATION CONTACT:
Associate General Counsel Philip Butler or Assistant General Counsel Edward Marcus at 202 3955725.
SUPPLEMENTARY INFORMATION:
A. Background In the course of this investigation the U.S. Trade Representative has imposed additional duties on products of China in four tranches. See 83 FR 28719 June 20, 2018; 83 FR 40823 August 16, 2018; 83 FR 47974 September 21, 2018 as modified by 83 FR 49153
September 28, 2018; and 84 FR 43304
August 20, 2019 as modified by 84 FR
69447 December 18, 2019 and 85 FR
3741 January 22, 2020.
For each tranche, the U.S. Trade Representative established a process by which U.S. stakeholders could request the exclusion of particular products subject to the action. The U.S. Trade Representative later established a process by which U.S. stakeholders could request the extension of particular exclusions. Additionally, on March 25, 2020, the U.S. Trade Representative requested public comments on possible further modifications to remove Section 301 duties from additional medical-care products to address the COVID19
pandemic. 85 FR 16987 March 25, 2020.
On December 29, 2020, USTR
announced the extension of 80 product exclusions on medical-care and/or COVID response products; further modifications, in the form of 19 product exclusions, to remove Section 301
duties from additional medical-care and/or COVID response products; and that USTR might consider further extensions and/or modifications as appropriate. See 85 FR 85831 the
PO 00000

Frm 00167

Fmt 4703

Sfmt 4703

December 29 notice. On March 10, 2021, USTR announced the extension of these 99 exclusions to September 30, 2021; and that USTR might consider further extensions and/or modifications as appropriate. See 86 FR 13785.
B. Request for Public Comments Subsequent to USTRs announcement of the extension of the 99 exclusions for COVID19 response products in March, the spread of COVID19 in the United States initially declined, and domestic production of certain products covered by these exclusions increased. With the recent spread of the Delta variant, COVID19 cases in the United States are increasing again. In light of these changing circumstances, including the ability of the United States to obtain certain products domestically or from other sources, USTR is requesting public comments on whether to extend particular exclusions for COVID19
products for up to six months.
USTR will evaluate each exclusion on a case-by-case basis. The evaluation will examine whether it remains appropriate to exclude certain products from the additional Section 301 duties in light of recent developments including the spread of the Delta variant in the United States and increased domestic production of certain products, and taking account of the overall impact of these exclusions on the goal of obtaining the elimination of Chinas acts, policies, and practices covered in this Section 301 investigation.
C. Procedures To Comment on Particular COVID19 Exclusions The 99 COVID exclusions can be found in the four annexes A, B, C, and D of the December 29 notice. To submit a comment regarding any particular COVID19 exclusion, a commenter first must register on the portal at https
comments.USTR.gov. As noted above, the public docket on the portal will be open from August 27, 2021, to September 27, 2021. After registration, the commenter may submit a comment form to the public docket. Fields on the comment form marked with an asterisk are required fields. Fields with a gray BCI notation are for business confidential information, which will not be publicly available. Fields with a green Public notation will be publicly available. Additionally, parties will be able to upload documents and indicate whether the documents are BCI or public. Commenters will be able to review the public version of their comments before they are posted.
Set out below is a summary of the information to be entered on the exclusion comment form.

E:FRFM27AUN1.SGM

27AUN1